BioSpace News Archive

Business

Novartis Sees Sharp Decline in Generic Drug Sales During First Quarter

Shares of Novartis are down nearly 3 percent this morning after the company reported a sharp decline in generic drugs and sales results from key branded medicines that missed analysts’ projections for the first quarter.

April 19, 2018

·

2 min read

·

Alex Keown

Business

FDA’s Chowdhury Leaves to Take Exec Position at AstraZeneca

Badrul Chowdhury, director of the U.S. Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER)’s Division of Pulmonary, Allergy and Rheumatology Products, has left the agency to take a position as senior vice president of research development at AstraZeneca and MedImmune.

April 19, 2018

·

3 min read

·

Mark Terry

FDA

AstraZeneca’s Tagrisso Nabs Another Lung Cancer Approval

The U.S. Food and Drug Administration (FDA) approved AstraZeneca’s Tagrisso (osimertinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) in tumors with epidermal growth factor receptor (EGFR) mutations.

April 19, 2018

·

2 min read

·

Mark Terry

Drug Development

Companies Advance Antimicrobial Treatments for Drug Resistant Bacteria

With growing concerns about the rise of drug resistant bacteria, multiple companies are developing new forms of antimicrobials to take on serious health concerns.

April 19, 2018

·

2 min read

·

Alex Keown

Business

Amgen Exec John Tsai to Head Novartis’ Global Drug Development

Novartis announced that John Tsai, formerly of Amgen, is joining the company as Head of Global Drug Development and chief medical officer.

April 19, 2018

·

1 min read

·

Mark Terry

Shire Under Pressure to Break Up the Business

Deals

UPDATED: Shire Rejects Takeda’s $60 Billion Acquisition Bid and Allergan Reportedly In Talks with Shire

Takeda Pharmaceutical has made an official bid to acquire London’s Shire for about $60 billion. And in breaking news, Shire rejected the bid, saying it undervalued the company.

April 19, 2018

·

4 min read

·

Mark Terry

Black clock with Review time, three-dimensional rendering, 3D illustration

Policy

Eli Lilly and Incyte Shares Drop as FDA Raises Concerns about Arthritis Drug

Ahead of next Monday’s U.S. Food and Drug Administration (FDA) committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis, concerns over blood clots, may scuttle the drug’s chances.

April 19, 2018

·

2 min read

·

Mark Terry

Business

BenevolentAI Grabs $115 Million to Advance its Drug Development Programs

The use of artificial intelligence and machine learning in drug development has been ramping up and investors are taking keen notice of the growing trend. This morning BenevolentAI snagged $115 million.

April 19, 2018

·

3 min read

·

Alex Keown

Job Trends

WuXi AppTec Expansion Will Create 200 New Jobs in New Jersey

With the cutting of a ribbon more than 200 new jobs are expected to be created as China-based WuXi AppTec officially opened its expanded Laboratory Testing Division (LTD) facility in New Jersey.

April 19, 2018

·

2 min read

·

Alex Keown

File folder with Merger and Acquisition and financial graphs. Business concept

Deals

P&G Acquires Merck KGaA’s Consumer Health Business, Pfizer Spurned Again

Pfizer’s consumer health business has been spurned again. This time by mega-consumer goods company Proctor & Gamble. which opted today to acquire Germany-based Merck KGaA’s consumer health unit for $4.2 billion.

April 19, 2018

·

3 min read

·

Alex Keown